Although this is an intuitive potential biomarker candidate, the present evidence (either in vitro or in vivo) to support using pERK as a predictive marker for Sorafenib in HCC therapy is preliminary. This evidence concerns the gene EIF2AK3 and hepatocellular carcinoma.